Search clinical trials for: BAY98-7443

Total 282 results

Bayer

Completed

A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components (INDessa)

Contraception

Germany, United Kingdom
Bayer

Completed

A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome

Functional and Motility Related Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia

Germany
Bayer

Completed

Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo

Irritable Bowel Syndrome

Germany
Bayer

Completed

Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function

Functional Gastrointestinal Disorders

Germany
Bayer

Completed

Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

Heart Failure

Germany
Bayer

Completed

Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus

Functional Gastrointestinal Disorders

Germany
Bayer

Terminated

Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients

Colitis, Ulcerative

Germany
Bayer

Completed

A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting

Functional Dyspepsia | Irritable Bowel Syndrome | Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia

Germany
Life Molecular Imaging SA

Completed

Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation

Neoplasms | Diagnostic Imaging

Korea, Republic of, United States, Germany
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

Pharmacokinetics

Germany
Bayer

Completed

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR) (ReFineDR)

Diabetic Retinopathy

Korea, Republic of, Russian Federation, Hong Kong, Taiwan, United States, Argentina, Japan, Denmark, Israel, Spain, Sweden, China, Colombia, Italy, Portugal
Life Molecular Imaging SA

Completed

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

Alzheimer Disease

United States, France, Japan, Australia, Germany
Bayer

Completed

Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

Atrial Fibrillation

Germany
Life Molecular Imaging SA

Completed

Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

Alzheimer Disease | Amyloid Beta-Protein

Australia
Life Molecular Imaging SA

Completed

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

Down Syndrome | Amyloid Beta-protein

United States
Kissei Pharmaceutical Co., Ltd.

Withdrawn

Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder

Overactive Bladder

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Phase II Study of KUC-7483 in Patients With Overactive Bladder

Overactive Bladder (OAB)

Japan
Bayer

Completed

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN)

Diabetic Nephropathies

Hong Kong, Australia, Spain, Portugal, United States, France, Canada, Netherlands, Austria, Finland, Poland, Taiwan, Hungary, Israel, Italy, South Africa, Sweden, Bulgaria, Germany, Denmark, Czechia, Korea, Republic of, Norway
Bayer

Terminated

A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF) (COMPOSE 2)

Acute Heart Failure

Belgium, France, Argentina, United States, Austria, Mexico, Germany, Philippines, Ireland
Bayer

Terminated

A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF) (COMPOSE EARLY)

Heart Failure | Heart Decompensation

Italy, United States, Germany, Spain, Japan, Canada, France, Hungary, Poland, South Africa, Korea, Republic of, Israel, Finland, United Kingdom, Ireland, Czech Republic
Boehringer Ingelheim

Completed

Study to Determine Pharmacodynamic Effects and Pharmacokinetics of KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity

Spinal Cord Injuries
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male Volunteers

Healthy
Bayer

Active, not recruiting

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Non-diabetic Chronic Kidney Disease

Hong Kong, United States, Spain, China, Belgium, Taiwan, Australia, Korea, Republic of, Russian Federation, United Kingdom, Singapore, Malaysia, Japan, Greece, Israel, Hungary, Italy, Czechia, Denmark, Argentina, Bulgaria, Mexico, I... and more
Bayer

Terminated

Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667

Congestive Heart Failure

Spain, Germany, Italy, United States, Canada, Hungary, Israel, Estonia, Slovenia, Croatia, Serbia, Lithuania, Poland, Sweden, Russian Federation, Czech Republic, United Kingdom
Life Molecular Imaging SA

Completed

Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

Neoplasms

United States
Bayer

Completed

A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

Chronic Kidney Disease | Worsening Chronic Heart Failure

Germany
Life Molecular Imaging SA

Completed

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

Alzheimer Disease | Amyloid Beta-Protein

United States, Switzerland, Australia, Germany, Japan
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

Pharmacokinetics

Germany
Bayer

Completed

Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

Oncology

United States
Bayer

Completed

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

Diabetic Nephropathies

Japan
Bayer

Recruiting

A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Chronic Kidney Disease

India
Bayer

Recruiting

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States, Germany, Argentina, Belgium, Brazil, Canada, Chile, Colombia, France, Italy, Korea, Republic of, Luxembourg, Mexico, Netherlands, Russian Federation, Saudi Arabia, Singapore, Slovenia, Spain, Switzerland, Taiwan, Th... and more
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD)

Chronic Kidney Disease

Belgium, Finland, France, China, Hong Kong, Switzerland, United States, Turkey, Greece, New Zealand, Poland, South Africa, Spain, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, ... and more
Bayer

Completed

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR) (DeFineDR)

Diabetic Retinopathy

United Kingdom, Bulgaria
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD)

Diabetic Kidney Disease

Belgium, Finland, France, Spain, China, Hong Kong, Switzerland, United States, Colombia, Turkey, Greece, New Zealand, Poland, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, Sweden, Austr... and more
Bayer

Terminated

BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF) (COMPOSE 1)

Acute Heart Failure

Israel, Italy, Japan, Switzerland, United States, Austria, Germany, Thailand, Romania, Slovenia, Croatia, Serbia, Russian Federation, Finland, Sweden, Poland, Slovakia
AbbVie

Terminated

A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer

Acute Myeloid Leukemia (AML)

United States
Bayer

Completed

Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Neoplasms

Japan
Bayer
Steigerwald Arzneimittelwerk GmbH

Completed

Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes

Moderate Depressive Episodes (Major Depression)
Bayer

Completed

Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles

Contraception

Russian Federation
Reata, a wholly owned subsidiary of Biogen

Completed

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

Glioma

United States
M.D. Anderson Cancer Center
Reata Pharmaceuticals, Inc.

Terminated

RTA 744 Injection in Patients With Leptomeningeal Disease

Lymphoma | Leukemia | Solid Tumor | Brain Tumor | Neoplastic Meningitis

United States
Yale University
Edison Pharmaceuticals Inc; Rembrandt Foundation

Completed

Open-Trial of EPI-743 for Adults With Tourette Syndrome

Tourette Syndrome

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of KUC 7483 Tablets in Healthy Male Volunteers

Healthy
Bayer

Completed

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants (FIGARO-BM)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Spain, Belgium, United States, Russian Federation, Hong Kong, Singapore, Taiwan, Korea, Republic of, Canada, Austria, Italy, Japan, Denmark, Australia, Bulgaria, Czechia, Finland, Israel, Netherlands, Sweden, Portugal
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bayer; Dendreon

Completed

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Prostate Cancer

United States
Edison Pharmaceuticals Inc

Completed

Phase 2 Study of EPI-743 for Treatment of Rett Syndrome

Rett Syndrome

Italy
Reata, a wholly owned subsidiary of Biogen

Terminated

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Brain Metastases

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

Healthy Volunteers

United States
Bayer

Recruiting

A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients (SMART-Finder)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Germany

3

Subscribe